Quebec is the first province in Canada to reimburse new drug developed to treat chronic hepatitis B
MONTREAL, CANADA – (February 8, 2007) – Bristol-Myers Squibb Canada announced today that Baraclude™, a drug administered orally to treat chronic hepatitis B virus infection, will be reimbursed by the Régime général d'assurance médicaments du Québec to naive patients and those who are refractory to current drugs.
Quebec is consequently the first province in Canada to enter Baraclude on its list to treat adults suffering from chronic hepatitis B virus infection, with evidence of active viral replication and either evidence of persistent elevations in serum levels of aminotransferases (ALT or AST) or histologically active disease.
"We're delighted with the Conseil du médicament's decision to make Baraclude available on the list of refundable drugs under Quebec's public plan. We're convinced that patients battling with hepatitis B will enthusiastically welcome the availability of a more effective alternative than the present treatment for chronic hepatitis B virus infection," stated Jean Paul Bédard, Vice-President, Corporate Affairs.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Company of Canada is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montreal, Quebec.
For further information, please contact:
Senior Manager of Public Affairs
Bristol-Myers Squibb Canada